皮下注射对比静脉注射埃万妥单抗联合拉泽替尼治疗难治性EGFR突变非小细胞肺癌:PALOMA-3研究的患者满意度和资源利用结果
PALOMA-3研究纳入EGFR突变非小细胞肺癌患者,随机接受皮下或静脉埃万妥单抗联合拉泽替尼。皮下组给药时间更短,患者对给药方式的不受限感和不困扰感比例更高,注射部位疼痛多为轻中度,多数患者偏好皮下给药。
要点
- 皮下组C1D1中位给药椅旁时间为23分钟(0.4小时),静脉组为6.5小时。
- 皮下组C1D1感觉不受限者66%,静脉组29%;不困扰者69%对30%。
- 皮下组注射部位中重度疼痛C1D1为14%,C3D1为16%。
核心结论
- 在PALOMA-3研究中,皮下埃万妥单抗简化并缩短给药,降低资源利用并提升治疗体验,是接受埃万妥单抗-拉泽替尼治疗患者的偏好选择。
研究设计与样本
- 3期PALOMA-3研究,EGFR突变非小细胞肺癌且奥希替尼和化疗后进展的患者随机接受皮下埃万妥单抗(n=206)或静脉埃万妥单抗(n=212),均联合拉泽替尼。
- 在周期1第1天和周期3第1天评估资源利用和患者报告的治疗满意度。
主要发现
- 椅旁时间皮下组显著低于静脉组:C1D1中位23分钟或0.4小时(范围0-12.0小时)对6.5小时(范围0-24.0小时);C3D1为35分钟或0.6小时(范围0-6.6小时)对3.4小时(范围0.5-9.0小时)。
- 医护人员时间和患者在室时间皮下组也低于静脉组。
- 感觉不受限者皮下组对静脉组:C1D1为66%对29%,C3D1为60%对42%。
- 不困扰者皮下组对静脉组:C1D1为69%对30%,C3D1为71%对45%;获得其他活动时间者皮下组对静脉组:C1D1为36%对7%,C3D1为37%对6%。
- 皮下组报告中度至非常严重注射部位疼痛者C1D1为14%、C3D1为16%;肿胀C1D1为5%、C3D1为6%;发红C1D1为5%、C3D1为6%。
关键数值与推荐
- 皮下埃万妥单抗给药时间中位C1D1为23分钟或0.4小时(范围0-12.0小时),C3D1为35分钟或0.6小时(范围0-6.6小时)。
- 静脉埃万妥单抗给药时间中位C1D1为6.5小时(范围0-24.0小时),C3D1为3.4小时(范围0.5-9.0小时)。
临床怎么用
- 皮下埃万妥单抗联合拉泽替尼可简化并缩短给药,降低资源利用并提升治疗体验,是接受该联合治疗患者的偏好选择。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Intravenous anticancer treatments present challenges for patients and healthcare professionals (HCPs), prompting the development of subcutaneous formulations. In the phase 3 PALOMA-3 study, subcutaneous amivantamab demonstrated noninferior pharmacokinetics and response rates versus intravenous amivantamab (both with lazertinib), with substantially faster administration, a 5-fold reduction in infusion-related reactions, reduced venous thromboembolism, and numerically prolonged survival. METHODS: Participants with EGFR-mutated NSCLC and progression on osimertinib and chemotherapy were randomized to subcutaneous (n = 206) or intravenous amivantamab (n = 212), plus lazertinib. Resource utilization and participant-reported treatment satisfaction were evaluated at cycle (C) 1 day (D) 1 and C3D1. RESULTS: Time-in-chair was substantially lower for subcutaneous versus intravenous amivantamab (C1D1: median [range], 23 min or 0.4 h [0-12.0 h] vs 6.5 h [0-24.0 h]; C3D1: 35 min or 0.6 h [0-6.6 h] vs 3.4 h [0.5-9.0 h]), as were HCP time and participant time-in-room. More participants who received subcutaneous versus intravenous amivantamab reported feeling unrestricted (C1D1, 66 % vs 29 %; C3D1, 60 % vs 42 %) or unbothered (C1D1, 69 % vs 30 %; C3D1, 71 % vs 45 %) by administration, and reported gaining time for other activities (C1D1, 36 % vs 7 %; C3D1, 37 % vs 6 %). Few participants who received subcutaneous amivantamab reported moderate-to-very severe injection-site pain (C1D1, 14 %; C3D1, 16 %), swelling (C1D1, 5 %; C3D1, 6 %), or redness (C1D1, 5 %; C3D1, 6 %). Most subcutaneous amivantamab recipients preferred and were more satisfied with its administration versus historical experience with intravenous therapies and would recommend it. CONCLUSIONS: In PALOMA-3, subcutaneous amivantamab, which simplifies and shortens administration, reduces resource utilization, and enhances treatment experience, was a preferred option for patients who received amivantamab-lazertinib.
引用
- Alexander M, Cheng Y, Lee SH, et al. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study. Eur J Cancer. 2025. PMID: 40730077. doi:10.1016/j.ejca.2025.115624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。